Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REGN
DateTimeSourceHeadlineSymbolCompany
27/04/201906:11Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:REGNRegeneron Pharmaceuticals Inc
27/04/201906:11Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:REGNRegeneron Pharmaceuticals Inc
27/04/201902:48Dow Jones NewsRegeneron, Sanofi Skin Cancer Drug Gets Warm Reception from European RegulatorsNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/04/201901:15PR Newswire (US)CHMP Issues Positive Opinion for Libtayo® (cemiplimab) in Advanced Cutaneous Squamous Cell CarcinomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
19/04/201909:05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
11/04/201907:13Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:REGNRegeneron Pharmaceuticals Inc
09/04/201906:01PR Newswire (US)Regeneron to Report First Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2019NASDAQ:REGNRegeneron Pharmaceuticals Inc
08/04/201921:00PR Newswire (US)Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular...NASDAQ:REGNRegeneron Pharmaceuticals Inc
08/04/201921:00Business WireAlnylam & Regeneron Announce Broad Collaboration to Discover, Develop & Commercialize RNAi Therapeutics Focused on Ocular & C...NASDAQ:REGNRegeneron Pharmaceuticals Inc
25/03/201922:40GlobeNewswire Inc.Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash National, and Regeneron Pharmaceutica...NASDAQ:REGNRegeneron Pharmaceuticals Inc
23/03/201907:05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
16/03/201907:01PR Newswire (US)Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with establish...NASDAQ:REGNRegeneron Pharmaceuticals Inc
13/03/201922:00PR Newswire (US)Regeneron and Sanofi to Present New Praluent® (alirocumab) Data at ACC.19NASDAQ:REGNRegeneron Pharmaceuticals Inc
13/03/201914:02PR Newswire (US)Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Class...NASDAQ:REGNRegeneron Pharmaceuticals Inc
13/03/201912:56PR Newswire (US)Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Class...NASDAQ:REGNRegeneron Pharmaceuticals Inc
13/03/201902:36PR Newswire (US)FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in AdolescentsNASDAQ:REGNRegeneron Pharmaceuticals Inc
12/03/201907:33Dow Jones NewsRegeneron Says FDA Approves Dupixent for Atopic Dermatitis in AdolescentsNASDAQ:REGNRegeneron Pharmaceuticals Inc
12/03/201906:45PR Newswire (US)FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescentsNASDAQ:REGNRegeneron Pharmaceuticals Inc
12/03/201906:44PR Newswire (US)FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in AdolescentsNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/03/201916:00PR Newswire (US)New Genetic Data from Regeneron and GSK on 50,000 UK Biobank Participants Made Available to Global Health Research CommunityNASDAQ:REGNRegeneron Pharmaceuticals Inc
09/03/201908:01PR Newswire (US)Regeneron Announces Upcoming Investor Conference CallNASDAQ:REGNRegeneron Pharmaceuticals Inc
08/03/201922:40Dow Jones NewsRegeneron, Sanofi Get FDA Priority Review for DupixentNASDAQ:REGNRegeneron Pharmaceuticals Inc
08/03/201916:59PR Newswire (US)FDA to Undertake Priority Review of Dupixent® (dupilumab) for Adults with Inadequately Controlled Severe Chronic Rhinosinusi...NASDAQ:REGNRegeneron Pharmaceuticals Inc
02/03/201900:35PR Newswire (US)CHMP Recommends Approval of Dupixent® (dupilumab) for Asthma IndicationNASDAQ:REGNRegeneron Pharmaceuticals Inc
01/03/201922:59PR Newswire (US)New Analyses to Be Presented at AAD for Dupixent® (dupilumab) and the Burden of Atopic DermatitisNASDAQ:REGNRegeneron Pharmaceuticals Inc
26/02/201910:22Dow Jones NewsAmgen Says Delaware Jury Upholds Co's Patents On RepathaNASDAQ:REGNRegeneron Pharmaceuticals Inc
26/02/201909:22PR Newswire (US)Regeneron and Sanofi Strongly Disagree with Verdict Upholding Three of Five Amgen U.S. Patent Claims Relating to PCSK9 Antibo...NASDAQ:REGNRegeneron Pharmaceuticals Inc
26/02/201904:44PR Newswire (US)Positive Results Presented from Two Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Poly...NASDAQ:REGNRegeneron Pharmaceuticals Inc
16/02/201908:42PR Newswire (US)U.S. and EU Patent Office Decisions Invalidate Amgen Subsidiary Immunex's Patents Claiming Antibodies to the IL-4 ReceptorNASDAQ:REGNRegeneron Pharmaceuticals Inc
15/02/201901:30PR Newswire (US)Regeneron Announces Upcoming Investor Conference PresentationNASDAQ:REGNRegeneron Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:REGN